Newron STARS Fade With Sarizotan Failure
Stock Sinks Over 70%
Sarizotan, licensed from Merck KGaA in 2011 for Rett syndrome, was seen as a potential gamechanger for Newron but the termination of the project leaves a huge hole in the Italian group's pipeline.
